Design Therapeutics, Inc. (NASDAQ:DSGN – Get Free Report) has been given a consensus recommendation of “Moderate Buy” by the eight research firms that are covering the stock, Marketbeat reports. One research analyst has rated the stock with a sell recommendation, six have issued a buy recommendation and one has issued a strong buy recommendation on the company. The average twelve-month price objective among brokers that have issued a report on the stock in the last year is $16.50.
DSGN has been the subject of a number of recent analyst reports. Cantor Fitzgerald assumed coverage on shares of Design Therapeutics in a research report on Tuesday, May 12th. They set an “overweight” rating for the company. Piper Sandler reiterated an “overweight” rating and set a $20.00 price target on shares of Design Therapeutics in a report on Wednesday, April 29th. Oppenheimer increased their price target on Design Therapeutics from $18.00 to $21.00 and gave the stock an “outperform” rating in a report on Monday, May 4th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Design Therapeutics in a report on Monday, April 20th. Finally, Wall Street Zen upgraded Design Therapeutics from a “sell” rating to a “hold” rating in a report on Sunday, May 10th.
Get Our Latest Report on Design Therapeutics
Institutional Inflows and Outflows
Design Therapeutics Price Performance
Design Therapeutics stock opened at $10.44 on Thursday. The business has a 50 day moving average of $12.29 and a 200-day moving average of $10.62. Design Therapeutics has a 1 year low of $3.33 and a 1 year high of $17.25. The company has a market capitalization of $652.08 million, a P/E ratio of -8.70 and a beta of 1.63.
Design Therapeutics (NASDAQ:DSGN – Get Free Report) last issued its quarterly earnings results on Tuesday, April 28th. The company reported ($0.29) earnings per share for the quarter, beating the consensus estimate of ($0.36) by $0.07. Equities analysts anticipate that Design Therapeutics will post -1.36 EPS for the current year.
About Design Therapeutics
Design Therapeutics, Inc a biopharmaceutical company, researches, designs, develops, and commercializes small molecule therapeutic drugs for the treatment of genetic diseases in the United States. The company utilizes its GeneTAC platform to design and develop therapeutic candidates for inherited diseases caused by nucleotide repeat expansion. Its lead product candidates for potentially disease-modifying treatment comprises Friedreich Ataxia, a monogenic, autosomal recessive, progressive multi-system disease that affects organ systems dependent on mitochondrial function that brings to neurological, cardiac, and metabolic dysfunction; Myotonic Dystrophy Type-1, a dominantly-inherited, monogenic progressive neuromuscular disease affecting skeletal muscle, heart, brain, and other organs; Fuchs Endothelial Corneal Dystrophy, a genetic eye disease characterized by bilateral degeneration of corneal endothelial cells and progressive loss of vision; and Huntington's Disease, a dominantly inherited, monogenic neurodegenerative disease characterized by movement, cognitive, and psychiatric disorders.
Featured Stories
- Five stocks we like better than Design Therapeutics
- Coke’s $10B India IPO Plan Pops the Top on Hidden Value
- FedEx Unboxes Billions in Post-Spinoff Value
- Marvell’s AI Moment Raises a Bigger Question for Amazon and ServiceNow
- Palo Alto Networks Accelerates Growth 31% on AI Demand
Receive News & Ratings for Design Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Design Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
